S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Top 5 Tech Stocks to Buy for 2024 (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Did You Get Your Free Bitcoin Yet? (Ad)
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Top 5 Tech Stocks to Buy for 2024 (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Did You Get Your Free Bitcoin Yet? (Ad)
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Top 5 Tech Stocks to Buy for 2024 (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Did You Get Your Free Bitcoin Yet? (Ad)
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Top 5 Tech Stocks to Buy for 2024 (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Did You Get Your Free Bitcoin Yet? (Ad)
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Free Trial
NASDAQ:ZEAL

Zealand Pharma A/S (ZEAL) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free ZEAL Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$17.59
▼
$17.59
50-Day Range
$16.54
▼
$19.20
52-Week Range
$9.93
▼
$32.94
Volume
N/A
Average Volume
4,965 shs
Market Capitalization
$818.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
ZEAL stock logo

About Zealand Pharma A/S Stock (NASDAQ:ZEAL)

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

ZEAL Stock News Headlines

April 12, 2024 | ft.com
A ghost of Brexit past returns to haunt Labour
April 4, 2024 | morningstar.com
U.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This Year
April 17, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
March 31, 2024 | msn.com
New Zealand cancer trial: CAR T-cell therapy for lymphoma, leukaemia and myeloma is saving lives
March 29, 2024 | msn.com
'Oppenheimer' director Christopher Nolan will receive a knighthood in the UK
March 28, 2024 | nz.finance.yahoo.com
Jessie J says she’s the opposite of a ‘beige mum’ as she shows off son’s playroom
March 28, 2024 | msn.com
New Zealand Education: International student enrolments top 59,000 for the first eight months of 2023
March 28, 2024 | msn.com
Ozempic maker Novo Nordisk gets more weight loss drug competition as a rival releases promising data
April 17, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
March 26, 2024 | globenewswire.com
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
March 26, 2024 | globenewswire.com
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
March 20, 2024 | globenewswire.com
Zealand Pharma's Annual General Meeting 2024
March 19, 2024 | globenewswire.com
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
March 17, 2024 | businessinsider.com
Weight loss drugs like Ozempic and Wegovy are fattening up Denmark's economy and helped it dodge a recession last year
March 15, 2024 | msn.com
What is amycretin? The new weight-loss pill that’s ‘twice as effective’ as Ozempic
March 14, 2024 | yahoo.com
Factbox-Madrigal's drug wins first US approval for fatty liver disease NASH as rivals circle
March 13, 2024 | globenewswire.com
New Employee Elected Directors to the Board of Zealand Pharma A/S
March 13, 2024 | msn.com
Who benefits from direct-to-consumer pharmaceutical advertising?
March 8, 2024 | globenewswire.com
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
March 5, 2024 | globenewswire.com
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
March 5, 2024 | globenewswire.com
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
March 1, 2024 | globenewswire.com
Zealand Pharma to Participate in TD Cowen's 44th Annual Health Care Conference
February 27, 2024 | finance.yahoo.com
Zealand Pharma A/S (ZEAL.CO)
February 27, 2024 | globenewswire.com
Zealand Pharma Announces Financial Results for the Full Year 2023
February 26, 2024 | cnbc.com
European markets close lower as investors await inflation data; Zealand Pharma up 35%
February 26, 2024 | uk.investing.com
Zealand Pharma stock soars 35% on strong trial results for its weight loss treatment
February 26, 2024 | msn.com
There might be a weight loss drug competitor to Ozempic — and the company's stock is soaring
See More Headlines
Receive ZEAL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/17/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ZEAL
CUSIP
N/A
CIK
1674988
Web
www.zealandpharma.com
Phone
(458) 877-3600
Fax
45-8877-3898
Employees
355
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($4.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-161,990,000.00
Net Margins
-565.44%
Pretax Margin
-364.34%
Return on Equity
-111.04%
Return on Assets
-56.54%

Debt

Debt-to-Equity Ratio
0.93
Current Ratio
4.79
Quick Ratio
4.78

Sales & Book Value

Annual Sales
$46.54 million
Price / Sales
17.59
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.38 per share
Price / Book
5.20

Miscellaneous

Outstanding Shares
46,538,000
Free Float
45,514,000
Market Cap
$818.60 million
Optionable
Not Optionable
Beta
1.45
10 Best Cheap Stocks to Buy Now Cover
10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Adam Sinding Steensberg M.D. (Age 48)
    Pres & CEO
    Comp: $680.16k
  • Mr. Ivan Mourits Moller (Age 50)
    Chief Operating Officer
  • Lani Pollworth Morvan
    Investor Relations & Communications Officer
  • Mr. Mads Kronborg
    Head of Investor Relations & Communication
  • Mr. Ravinder Chahil
    Sr. VP & Gen. Counsel
  • Ms. Christina Sonnenborg Bredal (Age 37)
    Sr. VP and Global Head of People & Organization
  • Ms. Hanne Heidenheim Bak (Age 69)
    Sr. Project Director, R&D Operations Mang. and Employee Representative Director
  • Dr. Jens Damsgaard Mikkelsen M.D.
    Head of Molecular Pharmacology
  • Dr. Danilo Verge
    Head of Global Medical Affairs
  • Dr. David M. Kendall M.D. (Age 60)
    Chief Medical Officer

Key Competitors

View All Competitors

ZEAL Stock Analysis - Frequently Asked Questions

Should I buy or sell Zealand Pharma A/S stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZEAL shares.
View ZEAL analyst ratings or view top-rated stocks.

How were Zealand Pharma A/S's earnings last quarter?

Zealand Pharma A/S (NASDAQ:ZEAL) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($4.61) EPS for the quarter, topping analysts' consensus estimates of ($6.31) by $1.70. The business earned $16.87 million during the quarter, compared to the consensus estimate of $12.21 million. Zealand Pharma A/S had a negative trailing twelve-month return on equity of 111.04% and a negative net margin of 565.44%. During the same quarter in the previous year, the company earned ($0.90) earnings per share.

What other stocks do shareholders of Zealand Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zealand Pharma A/S investors own include AbbVie (ABBV), Galapagos (GLPG), Verizon Communications (VZ), Dynavax Technologies (DVAX), EyePoint Pharmaceuticals (EYPT), Progenics Pharmaceuticals (PGNX), Portola Pharmaceuticals (PTLA), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE).

When did Zealand Pharma A/S IPO?

Zealand Pharma A/S (ZEAL) raised $75 million in an IPO on Wednesday, August 9th 2017. The company issued 3,900,000 shares at a price of $19.30 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

This page (NASDAQ:ZEAL) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
Banyan Hill Publishing
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
Top 5 Tech Stocks to Buy for 2024
Daily Market Alerts
AI healthcare stock poised for 36,996% growth?
Behind the Markets
New Trump Bombshell
The Freeport Society
A.I. Pioneer Issues Urgent Warning to Americans
TradeSmith